Cyprotex expects full year results to be ahead of expectations

Preclinical discovery and development contract researcher Cyprotex said trading had been ahead of expectations in the first nine months of the year.

The London-listed group said its financial performance in the three quarters to September had outpaced its own forecast, largely thanks to a strong showing from its UK business, while the environment for the US division remained challenging.

However, Cyprotex indicated its operations in the US have improved from 2014 and it expects overall revenue and earnings before interest, taxation, depreciation and amortisation for 2015 to be ahead of market expectations.

Cyprotex shares were up 11.45% to 73.00p at 1040 BST on Friday.